Design of new oxazaphosphorine anticancer drugs

Liang, Jun, Huang, Min, Duan, Wei, Yu, Xue-Qing and Zhou, Shufeng 2007, Design of new oxazaphosphorine anticancer drugs, Current pharmaceutical design, vol. 13, no. 9, pp. 963-978.

Attached Files
Name Description MIMEType Size Downloads

Title Design of new oxazaphosphorine anticancer drugs
Author(s) Liang, Jun
Huang, Min
Duan, Wei
Yu, Xue-Qing
Zhou, Shufeng
Journal name Current pharmaceutical design
Volume number 13
Issue number 9
Start page 963
End page 978
Publisher Bentham Science Publishers Ltd.
Place of publication Hilversum, The Netherlands
Publication date 2007-03
ISSN 1381-6128
1873-4286
Keyword(s) oxazaphosphorine
cyclophosphamide
ifosfamide
trofosfamide
glufosfamide
mafosfamide
Summary The oxazaphosphorines including cyclophosphamide (CPA, Cytoxan, or Neosar), ifosfamide (IFO, Ifex) and trofosfamide (Ixoten) represent an important group of therapeutic agents due to their substantial antitumor and immunomodulating activity. However, several intrinsic limitations have been uncounted during the clinical use of these oxazaphosphorines, including substantial pharmacokinetic variability, resistance and severe host toxicity. To circumvent these problems, new oxazaphosphorines derivatives have been designed and evaluated with an attempt to improve the selectivity and response with reduced host toxicity. These include mafosfamide (NSC 345842), glufosfamide (D19575, β-Dglucosylisophosphoramide mustard), S-(-)-bromofosfamide (CBM-11), NSC 612567 (aldophosphamide perhydrothiazine) and NSC 613060 (aldophosphamide thiazolidine). Mafosfamide is an oxazaphosphorine analog that is a chemically stable 4-thioethane sulfonic acid salt of 4-hydroxy-CPA. Glufosfamide is IFO derivative in which the isophosphoramide mustard, the alkylating metabolite of IFO, is glycosidically linked to a β-D-glucose molecule. Phase II studies of glufosfamide in the treatment of pancreatic cancer, non-small cell lung cancer (NCSLC), and recurrent glioblastoma multiform (GBM) have recently completed and Phase III trials are ongoing, while Phase I studies of intrathecal mafosfamide have recently completed for the treatment of meningeal malignancy secondary to leukemia, lymphoma, or solid tumors. S-(-)- bromofosfamide is a bromine-substituted IFO analog being evaluated in a few Phase I clinical trials. The synthesis and development of novel oxazaphosphorine analogs with favourable pharmacokinetic and pharmacodynamic properties still constitutes a great challenge for medicinal chemists and cancer pharmacologists.
Language eng
Field of Research 110404 Traditional Chinese Medicine and Treatments
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2007, Bentham Science Publishers Ltd.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30007440

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 20 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 499 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 29 Sep 2008, 08:52:08 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.